Proteins and Peptides

10 Nov 2016 Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee
10 Nov 2016 Novo Nordisk submits application in the EU for including data from the two SWITCH trials in Tresiba® label
10 Nov 2016 Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma
10 Nov 2016 Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types
10 Nov 2016 Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
09 Nov 2016 RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259
08 Nov 2016 The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
08 Nov 2016 Cerenis Therapeutics Announces Last Patient Dosed in CARAT Phase II Study with CER-001 in Post-Acute Coronary Syndrome Patients
06 Nov 2016 Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity
04 Nov 2016 Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease
04 Nov 2016 Nutrinia Announces First Patient Enrolled in Phase III Trial
04 Nov 2016 Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency
04 Nov 2016 Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
04 Nov 2016 Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis
02 Nov 2016 Spyryx Biosciences Presents Data at NACFC on SPX-101 Demonstrating Efficacy, Safety, and Stability in Animal Models
02 Nov 2016 Bremelanotide Meets Co-Primary Endpoints in Palatin's Phase 3 Trials for Hypoactive Sexual Desire Disorder
28 Oct 2016 The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin
27 Oct 2016 amcure Initiates Clinical Study in Patients to Test Novel Approach for Treating Advanced and Metastatic Cancers
26 Oct 2016 National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline
26 Oct 2016 Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout
26 Oct 2016 Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label
26 Oct 2016 EVARREST® Fibrin Sealant Patch Gains FDA Approval on Expanded Indication for General Hemostasis
26 Oct 2016 ProMetic's plasminogen meets primary and secondary end points in pivotal Phase 2/3 trial
26 Oct 2016 Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves’ Disease
25 Oct 2016 Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex® in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound Care

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top